ArticleJournal of biological engineering2026
Clitocine suppresses TNBC progression by boosting CCRL2 to block survival signals and neutrophil-driven inflammation.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study investigates the anti-tumor mechanisms of clitocine, a natural compound, in triple-negative breast cancer (TNBC), with a focus on its role in modulating the immune microenvironment via C-C motif chemokine receptor like 2 (CCRL2). The anti-cancer effects of clitocine were assessed in vitro using TNBC cell lines (MDA-MB-231 and MDA-MB-468) through functional assays, flow cytometry, and immunoblotting. RNA sequencing was performed to identified clitocine-induced transcriptional changes. The subcutaneous 4T1 xenograft models in BALB/c mice were used for in vivo validation. Additionally, mass cytometry (CyTOF) profiled tumor immune infiltration in tumor tissues, and the role of CCRL2 in modulating the tumor immune microenvironment and inflammatory pathways was investigated through database mining (TCGA) and gain/loss-of-function experiments.
resultsClitocine potently inhibits TNBC cell proliferation, metastasis, and epithelial-mesenchymal transition (EMT), while inducing mitochondrial apoptosis. It alters cancer-related gene expression (upregulating CCRL2), suppresses PI3K-AKT, NFκB, and ERK pathways, and exhibits potent antitumor activity in vivo without systemic toxicity. Mechanistically, clitocine remodels the tumor immune microenvironment by reducing neutrophil infiltration and suppressing neutrophil extracellular traps (NETs) formation, effects mediated through the CCRL2/chemerin axis. Furthermore, CCRL2 is identified as a tumor suppressor, with low expression in TNBC patients correlating with poor survival. Credibly, CCRL2 knockdown in vitro and in vivo significantly abrogates the anti-tumor and immunomodulatory effects of clitocine.
conclusionOur findings demonstrate that clitocine exerts potent anti-TNBC effects by upregulating CCRL2 expression, thereby activating the clitocine/CCRL2/chemerin axis. This axis disrupts critical oncogenic signaling pathways and reprograms the immunosuppressive tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.